A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in patients with uncontrolled hypertension who fail to respond adequately to treatment with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg.
- Conditions
- essential hypertensionMedDRA version: 6.1Level: HLGTClassification code 10057166
- Registration Number
- EUCTR2005-002442-19-IT
- Lead Sponsor
- BOEHRINGER ING.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1600
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antihypertensive effects of telmisartan plus hydrochlorothiazide in RAAS pathway modulation?
How does the EUCTR2005-002442-19-IT trial compare the efficacy of 25 mg vs 12.5 mg hydrochlorothiazide in treatment-resistant hypertension?
Which biomarkers correlate with response to telmisartan-based fixed-dose combinations in patients with essential hypertension?
What adverse events are associated with escalating hydrochlorothiazide doses in telmisartan combination therapy for uncontrolled hypertension?
How do telmisartan plus hydrochlorothiazide combinations compare to other ARB-thiazide diuretic regimens in managing resistant hypertension?